Insulin glargine-yfgn (Semglee) is biosimilar to and interchangeable with insulin glargine (Lantus), a long-acting insulin analog.

At the end of July, the FDA approved Semglee (insulin glargine-yfgn) as the first-ever interchangeable drug in the United States. It is essentially a copy of Lantus, a long-acting basal insulin.

Semglee (insulin glargine-yfgn) is an interchangeable biosimilar insulin product with its reference product Lantus (insulin glargine) manufactured by Sanofi.